A systematic review of the Da Vinci® Single-Port system (DVSP) in the context of colorectal surgery

Purpose: The purpose of this study is to review the application of the da Vinci® Single-Port system (DVSP) in colorectal surgery, with a view to assessing its safety and feasibility, and investigating its clinical and oncological outcomes. Methods: A comprehensive search of the scientific literature was conducted across three major databases (PubMed, Web of Science, and Cochrane) up to November 2024. The study was registered in PROSPERO (CRD42024612762) and conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Included studies pertained to the utilisation of DVSP in the domain of colorectal surgery. Results: Eleven articles were included in the final analysis. No randomized controlled trials were identified. A total of 396 patients (199 men, 197 women) underwent robotic colorectal surgery using the DVSP. Surgical resections were indicated for benign pathology in 56 patients, colon carcinoma in 194 cases, and rectal carcinoma in 146 cases. The median incision length for Uniport placement was 4 cm. The median docking time was 5.96 min (IQR, 9.33 min), and the median console time was 105 min (IQR, 62.51 min). The mean operative time was 186.3 min (IQR, 77.65 min). Intraoperative complications were rare, with only two cases reported (0.47%). Postoperative complications occurred in 12.47% of patients, with ileus being the most common. No patients were readmitted for complications within 30 days. Short-term oncological outcomes seemed promising, with a median of 24.59 lymph nodes retrieved. There were no reported deaths within 30 days. The median follow up time was 11.4 months (IQR, 11.76 months). Conclusion: This study shows that the use of DVSP in colorectal surgery is both feasible and safe. Short-term clinical and oncological outcomes seem promising. However, longer follow-up data and larger patient cohorts are needed to fully assess the long-term efficacy of this novel technique. Prospero registry: Registration number CRD42024612762.